GlassScriptPhysician profile
Jonathan N Posey
NPI 1922366145
$742.48
in general payments reported to CMS, 2019-2025
16 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $63.35 · 2022: $33.45 · 2023: $16.77 · 2024: $245 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $148.41 | 2025 | Zepbound, Mounjaro, Kisunla |
| Shockwave Medical, INC | $148.38 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $76.34 | 2023-2025 | Proclaim |
| Novo Nordisk INC | $48.73 | 2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $47.23 | 2022-2025 | Inceptiv |
| Axonics, INC. | $44.77 | 2020 | |
| Biogen, INC. | $36.01 | 2025 | Leqembi |
| Astrazeneca Pharmaceuticals LP | $35.42 | 2024-2025 | Farxiga, Lokelma |
| Corcept Therapeutics | $31.78 | 2024-2025 | Korlym |
| Recordati_rare_diseases_inc. | $23.12 | 2025 | Isturisa |
| Phathom Pharmaceuticals, INC. | $19.47 | 2025 | Voquezna |
| Pfizer INC. | $18.58 | 2020 | |
| Nevro Corp. | $17.97 | 2024 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $17.21 | 2025 | Trintellix |
| Amgen INC. | $15.31 | 2025 | Evenity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $13.75 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Posey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.